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ABSTRACT:
The analysis of protein modiﬁcation by electrophiles is a challenging problem. Most reported proteinelectrophile adducts have
been characterized from in vitro reactions or through aﬃnity capture of the adduct moiety, which enables global analyses but is
poorly suited to targeted studies of speciﬁc proteins. We employed a targeted molecular probe approach to study modiﬁcations of
themolecularchaperoneheatshockprotein90(Hsp90),whichregulatesdiverseclientproteins.Noncovalentaﬃnitycapturewitha
biotinylgeldanamycin probe isolated both isoforms of the native protein (Hsp90R and Hsp90β) from human RKO colorectal
cancer cells. Geldanamycinbiotin capture aﬀorded higher purity Hsp90 than did immunoprecipitation and enabled detection of
endogenously phosphorylated protein by liquid chromatographytandem mass spectrometry (LC-MS/MS). We applied this
approachtomapandquantifyadductsformedonHsp90by4-hydroxynonenal(HNE)inRKOcells.LC-MS/MSanalysesoftryptic
digestsbyidentiﬁedHis
450andHis
490ofHsp90Rashavinga158Damodiﬁcation,correspondingtoNaBH4-reducedHNEadducts.
FivehistidineresidueswerealsoadductedonHsp90β:His
171,His
442,His
458,His
625,andHis
632.Theratesofadductionatthesesites
were determined with Hsp90 protein in vitro and with Hsp90 in HNE-treated cells with a LC-MS/MS-based, label-free relative
quantitation method. During in vitro and cell treatment with HNE, residues on Hsp90R and Hsp90β displayed adduction rates
rangingfrom3.010
5h
1to1.08(0.17h
1.Withinthemiddleclient-bindingdomainofHsp90R,residueHis
450demonstrated
the most rapid adduction with kobs of 1.08 ( 0.17 h
1 in HNE-treated cells. The homologous residue on Hsp90β, His
442, was
adducted more rapidly than the N-terminal residue, His
171, despite very similar predicted pKa values of both residues. The Hsp90
middleclient-bindingdomainthusmayplayasignicantroleinHNE-mediateddisruptionofHsp90clientproteininteractions.The
results illustrate the utility of a protein-selective aﬃnity capture approach for targeted analysis of electrophile adducts and their
biological eﬀects.
’INTRODUCTION
Oxidativestressleadstotheformationofreactivelipid-derived
electrophiles. Species such as 4-hydroxy-2-nonenal (HNE) and
malondialdehyde are generated from either radical or enzyme-
mediated oxidation of polyunsaturated fatty acids such as arachi-
donic acid and linoleic acid. These species can covalently modify
proteins and DNA, thus inducing mutation and changes in
cellular signaling.
13 HNE adduction, in particular, is known to
aﬀect the activity of modiﬁed proteins.
46 Furthermore, HNE-
adducted proteins have been identiﬁed in the plasma of children
with autoimmune disease and in hepatocytes from rats fed a fat-
and ethanol-rich diet, suggesting the involvement of such mod-
iﬁcations in inﬂammatory disease and cancer.
4,5,7
Recently, HNE has been shown to induce activation of heat
shock transcription factor 1 and its nuclear localization in RKO
cells after treatment at concentrations above 30 μM.
8 Activation
of heat shock transcription factor 1 (Hsf1) occurs upon its
dissociation from the heat shock chaperone complex, consisting
of heat shock protein 90 (Hsp90), heat shock protein 70
(Hsp70), and Hsf1.
9 Hsp90 is a molecular chaperone with four
isoforms: Hsp90R, Hsp90β, TRAP1, and Grp94. Of the two
cytosolic forms, Hsp90R is inducible, whereas Hsp90β is con-
stitutive; Grp94 is found in the endoplasmic reticulum and
TRAP1 is the mitochondrial isoform. Hsp90 is an important
therapeutictargetfortreatmentofavarietyofcancersdependent
on chaperone-mediated stabilization of oncogenic proteins.
Several classes of Hsp90 inhibitors have been discovered and
developed for binding to the N-terminal ATPase domain.
10 The
client proteins of Hsp90 span many classes of protein function
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and the chaperone protein can act as a repressor of proteins
through inhibition by binding, as well as by stabilizing clients
againstdegradationbytheproteosome.
11,12Hsp90functionsasa
homodimer in the cytoplasm of cells, making up 12% of the
total protein content of normal cells and up to 6% of the protein
content in cancer cells.
Both Hsp90 and Hsp70 have been identiﬁed previously as
targets of electrophilic modiﬁcation in studies of rats fed with
ethanol-richdiets and in proteomic inventories of HNE-adducted
proteins in cell models.
4,5,13,14 In a previous study by Carbone
et al., a single site of HNE modiﬁcation of Hsp90 at Cys
572 was
identiﬁed after in vitro HNE treatment of puriﬁed protein and
subsequent analysis by liquid chromatographytandem mass
spectrometry (LC-MS/MS). Modiﬁcation of Hsp90 with
HNE was shown to reduce the chaperone activity of the
protein.
4
The literature thus indicates that Hsp90 is a HNE target, but
the only available data on site-speciﬁc adduction is from an in
vitro study with puriﬁed protein. Mapping and quantitative
comparison of site-speciﬁc adduction reactions on individual
proteins remains a daunting analytical challenge. We and others
have employed aﬃnity-tagged electrophiles for this purpose,
1316
but this strategy requires appropriate analogues and capture
chemistriesandcapturesallmodiﬁedproteinsratherthanjustthe
protein of interest. Others have used aﬃnity-based probes that
capture protein subclasses, such as kinases
17,18 or serine hydro-
lases,
19 but these approaches also do not enable selective target-
ing of individual proteins.
We addressed this problem by employing an aﬃnity-tagged
inhibitorofHsp90tocapturetheproteinfromcelllysatesforLC-
MS/MS analysis. The inhibitor is a derivative of geldanamycin, a
natural product that selectively targets Hsp90 and binds in the
N-terminal ATPase domain.
20 Geldanamycin induces a confor-
mational change that results in the release of the Hsp90 client
proteins and cochaperones. We demonstrate here that the com-
mercially available reagent,
21 geldanamycinPEGbiotin, will
isolate both cytosolic forms of Hsp90. We used geldanamycin
biotin capture and LC-MS/MS to characterize sites of HNE
modiﬁcation of Hsp90 in RKO cells treated with exogenous
HNE. We compared geldanamycinbiotin capture to Hsp90
immunoprecipitation and demonstrated detection of endogen-
ousHsp90phosphorylationsonproteinisolatedfromRKOcells.
We characterized adduction sites on Hsp90 captured from cells
a n dt r e a t e di nv i t r ow i t hH N E .W ea l s oi d e n t i ﬁed additional
adduction sites on both Hsp90R and Hsp90β isolated from
HNE-treated RKO cells. Reaction rates for HNE adduction
at several sites on both isoforms of Hsp90 both in vitro and in
intact cells were characterized by combining geldanamycin
biotin capture with targeted, label-free LC-MS/MS quantitation.
Our results demonstrate the utility of protein-selective aﬃnity
capture for targeted analysis of electrophile adducts and their
biological eﬀects.
’MATERIALS AND METHODS
Reagents. Geldanamycin and geldanamycinbiotin were purchased
from Enzo Life Sciences (Plymouth Meeting, PA). High-capacity Neutra-
vidinagaroseresinwasacquiredfromThermoScientific(Rockford,IL).All
media were purchased from Invitrogen (Carlsbad, CA). Mouse mono-
clonal anti-Hsp90 used for Western blotting was purchased from BD
Biosciences (San Jose, CA). Rabbit polyclonal anti-Hsp90 (Santa Cruz
Biochemicals, Santa Cruz, CA) and protein G agarose (Roche Applied
Science,Indianapolis,IN)wereusedforimmunoprecipitationofHsp90.
Modified sequence grade porcine trypsin was purchased from Promega
(Madison, WI). HNE was purchased from Cayman Chemicals (Ann
Arbor, MI) or synthesized as described.
14 Unless otherwise stated,
chemicals were purchased from Sigma and used as received.
Cell Culture. The human colon carcinoma cell line, RKO, was
obtained from ATCC and maintained in McCoy’s 5a medium supple-
mented with 10% fetal bovine serum. Cell treatments for less than 6 h
were performed at 7080% confluence in McCoy’s 5a medium lacking
serum. Treatments for longer than 6 h were performed in medium
containing 5% fetal bovine serum. Cells were harvested in medium,
pelleted, and then washed with 1 PBS before storage at 80C.
Isolation of Hsp90 with GeldanamycinBiotin. Cell pellets
were resuspended in lysis buffer (50 mM HEPES, pH 7.5, 150 mM
NaCl, 0.5% Igepal, 0.5 mM 4-(2-aminoethyl) benzenesulfonyl fluoride
hydrochloride, 0.5μMaprotinin,10μMleupeptin,1.4μME-64,20μM
betastatin, 1.5 μM pepstatin A, 1 mM NaF, and 10 mM β-glycero-
phosphate), sonicated, and clarified by centrifugation. Bicinchoninic
acid(ThermoFisherScientific,Rockford,IL)wasusedtodeterminethe
protein concentration. Geldanamycinbiotin(40μgi nD M S O ,2 0μg/μL
stock) was added to 250 μL of 1 mg/mL diluted lysate and incubated at
least 3 h at 4 C. Before application to the resin, the lysate was further
diluted to 0.25 mg/mL protein concentration in a volume of 1 mL.
Neutravidinagarose resin (375 μL slurry volume) was washed twice
with lysis buffer before the addition of diluted lysates containing the
affinity capture agent. The lysate and resin were incubated together at
4Covernight,afterwhichtheresinwaswashedfourtimeswith1mLof
lysis buffer before elution in 150 μL of either SDS-PAGE loading buffer
with 100 mM DTT or 2 mM geldanamycinbiotin in lysis buffer. The
eluted proteins were purified by gel electrophoresis on an 8 cm  8 cm,
10% polyacrylamide gel (Invitrogen) in the MOPS SDS running
buffer system. The protein was analyzed by either immunoblot
assay or LC-MS/MS analysis. For LC-MS/MS, the gel was stained
with SafeStain Blue (Invitrogen) and the desired band was excised,
reduced with 15 mM dithiothreitol for 15 min at 50 C, alkylated with
10 mM iodoacetamide, and finally digested in-gel with trypsin (0.001
mg/mL).
Immunoprecipitation of Hsp90. Cell pellets were resuspended
in lysis buffer (same as above), sonicated, and then clarified by
centrifugation for 15 min at 15000g. Immunoprecipitations were
performed with lysates diluted to 500 μg/mL of protein. Polyclonal
anti-Hsp90 (20 μg) was added to 1 mL of dilute lysate and incubated
with rotation overnight at 4 C. Protein G-agarose was added to the
lysate the following day and incubated at 4 C for at least 3 h. The resin
was washed four times with 1 mL of lysis buffer before elution of Hsp90
from the resin in SDS-PAGE loading buffer by heating at 95 C for 10
min. The immunoprecipitated Hsp90 was separated from the antibody
bySDS-PAGE,andeithertheproteinbandwasexcisedandsubjectedto
in-gel digestion and analysis by LC-MS/MS or the immunoprecipitate
was analyzed by immunoblot assay.
Treatment of Isolated Hsp90 with HNE. Hsp90 was isolated
from untreated RKO cells grown to a confluency of 7080%, as
described above. After washing the Neutravidin resin containing the
captured Hsp90 with NETN buffer, a final wash with 1 PBS at pH 7.5
wasperformed.HNEwasdilutedin100μLofPBStoaconcentrationof
1.0mMandaddedtotheHsp90proteinboundtotheNeutravidinresin,
which gave a final volume of 400 μL and a final HNE concentration of
250 μM. The resin was incubated for various times, with rotation at
room temperature. The reaction mixture was quenched with the
addition of 2 M NaBH4 to 10 mM and then frozen for subsequent
analysis. The Hsp90 was released from the resin and gel purified as
described above. The bands corresponding to Hsp90 were excised and
the protein was alkylated and digested for LC-MS/MS analysis as
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Treatment of Cells with HNE and Isolation of Hsp90. RKO
cells were grown to 8090% confluence in McCoy’s 5a medium
containing 10% FBS. The medium was aspirated and fresh medium
with HNE was added to the cells. The cells were incubated with the
electrophile for 1 h (unless otherwise noted) at 37 C until being
harvested in the culture medium. The harvested cells were washed once
with 1 PBS before freezing. Cell lysates were prepared as described
above. Afterrapid geldanamycinbiotinisolation (incubationtimewith
geldanamycinbiotin was reduced to 1 h and incubation with neutra-
vidin resin reduced to 1.5 h at 4 C), neutravidin resin was washed four
times with 1.0 mL of lysis buffer. The final wash was removed and 1/10
resinvolume(50μLfor500μLbedvolumeresin)of10mMNaBH4was
added to the resin. This slurry was incubated with rotation for 30 min at
room temperature. After incubation, 1/5 bed volume of SDS loading
buffer was added to the resin and incubated at 95 C for 10 min to elute
Hsp90. This sample was then analyzed by gel electrophoresis and the
Hsp90 band was excised for digestion and analysis by LC-MS/MS as
described above.
LC-MS/MS Analysis. Initial LC-MS/MS analyses of the geldana-
mycincapture andimmunoprecipitation ofHsp90were performed with
a Thermo LTQ instrument (ThermoFisher, San Jose, CA) equipped
with an Eksigent solvent delivery system, autosampler, and a microelec-
trospray source. Peptides were resolved on a 100 μm  11 cm fused
silica capillary column (Polymicro Technologies, LLC, Phoenix, AZ)
packed with 5 μm, 300 Å Jupiter C18 (Phenomenex, Torrance, CA).
Liquidchromatographywascarriedoutatambienttemperatureataflow
rate of 0.6 μL/min using a gradient mixture of0.1% (v/v) formic acidin
water(solventA)and0.1%(v/v)formicacidinacetonitrile(solventB).
Peptides eluting from the capillary tip were introduced into the LTQ
source with a capillary voltage of approximately 2.4 kV. The heated
capillary was operated at 150 C and 40 V. MS/MS spectra were
acquired in the data-dependent scanning mode, consisting of a full scan
obtainedforelutingpeptidesintherangeof3502000m/z,followedby
four data-dependent MS/MS scans. MS/MS spectra were recorded
usingdynamicexclusionofpreviouslyanalyzedprecursorsfor30switha
repeat duration of 2 min. MS/MS data were analyzed using the
SEQUEST algorithm for database searching and IDPicker for protein
group assembly.
22,23
To provide accurate mass characterization of HNE adducts on
Hsp90, a Thermo LTQ-Orbitrap instrument with an Eksigent Nano
1D Plus pump and autosampler (Eksigent Technologies, Dublin, CA)
was used to analyzeHsp90 samples from treated cells andfrom on-resin
HNE treatments. Liquid chromatography was performed as described
above. The data-dependent inclusion list screening was carried out with
the following parameters, derived from previously described methods.
24
An Orbitrap MS scan from m/z 3002000 at 60000 resolution was
followedby10LTQiontrapMS/MSscans.Ifeightormoreionsonthe
inclusion list were present, then the eight most intense ions were
selected for tandem MS analysis. If less than eight ions on the inclusion
list were present, then those ions plusthe most intense ions in the initial
scanupto8weretargeted.Dynamicexclusionwasenabled,witharepeat
count of 3 and a repeat duration of 10 s. The exclusion list size was 50,
and the exclusion duration was 20 s. Threshold intensity for triggering
peakdetectionwassetat100withacollisionenergyof28%fortheentire
list. The data were analyzed using MonsterMod, an algorithm similar to
PMod,
25 to identify MS/MS spectra corresponding to Hsp90 peptides
withmassshiftsgreaterthan1Da.Massshiftsof158Dacorrespondedto
thereducedMichaeladductsofHNE.Spectraoftheadductedprecursor
and fragment ions were veriﬁed manually, with a requirement of less
than 10 ppm error for peptide adduct precursor m/z measurements.
Kinetic Analysis of Hsp90 Adduction. Kinetic analysis of
modification sites was performed using a label-free quantitation approach
we described previously.
26 This approach measures signals for adducted
peptidesbyLC-MS/MSusingaThermoLTQinstrument.Eachpeptide
adduct was monitored by targeting the m/z of the doubly or triply
charged precursor for MS/MS. Two unmodified peptides from each
protein were also targeted in the same manner (see Supporting
Information Table 2). Specific product ions generated by MS/MS
fragmentation of the targeted peptide adducts and reference peptides
were extracted with Thermo Xcalibur software, and peak areas were
integrated. Three product ion signals were monitored for each peptide
or peptide adduct and the peak area for each MS/MS transition were
summed to generate a peak area for each peptide. MS/MS data for both
doubly and triply charged precursor ions were acquired in some cases
and the product ions yielding the greatest signal were used for
subsequent analysis. The peak area of each peptide adduct was normal-
ized to the average signal of the two unmodified reference peptides at
each sample time point. The peak area reflecting HNE adduction after
24 h treatment was used as the end point for reactions with isolated
Hsp90inordertodetermineanobservedrateofreaction.Foranalysesof
adduction by HNEtreatment inintact cells, a4 h timepoint wasused as
an end point. Values of kobs were calculated from plots of the ratio of
normalized peak areas for adducted peptides at each time point to the
average normalized peak area for the adducted peptide at the specified
endpoint.DatawerefittedtoasingleexponentialassociationwithPrism
(GraphPad Software, La Jolla, CA).
’RESULTS
GeldanamycinBiotin Isolates Both Isoforms of Hsp90
from Cell Lysates. To identify sites of HNE modification of
Hsp90, a biotin-tagged analogue of the Hsp90 inhibitor, geldana-
mycin,wasusedtocaptureendogenousproteinfromthelysatesof
treated and untreated cells. This compound, geldanamycin
biotin (Scheme 1), binds tightly to all isoforms of Hsp90 and
displaces proteins bound to Hsp90 by inducing conformational
changes around the ATP-binding site.
21 As shown in Figure 1A,
capture with geldanamycinbiotin was more efficient than
immunoprecipitation of the native Hsp90. The captured target
protein was eluted either with 2 mM geldanamycin or by boiling
in SDS-PAGE loading buffer. Very little protein bound to the
neutravidin resin alone, as observed in the negative control lanes
shown in Figure 1A. LC-MS/MS shotgun analysis of the
immunoprecipitation eluent identified Hsp90 and 79 other
proteins, whereas analysis of the geldanamycinbiotin capture
eluent identified only five proteins other than Hsp90. The
identity of the protein band at 90 kDa was confirmed as Hsp90
Scheme 1. Chemical Structure of Hsp90 Capture Agent,
GeldanamycinBiotin1278 dx.doi.org/10.1021/tx200157t |Chem. Res. Toxicol. 2011, 24, 1275–1282
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by immunoblotting with an anti-Hsp90 antibody (Figure 1B).
(ThisantibodydoesnotdistinguishHsp90RandHsp90β,which
migrate together on the gel.) The eluted Hsp90 was analyzed by
LC-MS/MStodetectpost-translationalmodifications.Sequence
coverage of Hsp90 from analysis of three biological replicate
samples was above 75% for both Hsp90R and Hsp90β (see
Supporting Information Table 1 for representative peptide list).
Hsp90 is known to be phosphorylated at two sites, Ser
226β/231R
and Ser
255β/263R, although the responsible kinase has not yet
been identified.
27 These phosphorylation sites were routinely
observed in Hsp90 isolated from untreated RKO cells (see
Supporting Information Table 1 and Figures 12.)
Identification of Modification Sites Using in Vitro Treat-
ment of Captured Hsp90. We identified potential sites of
modification on Hsp90 using in vitro treatment of Hsp90 captured
from RKO cells. Hsp90 was captured from untreated RKO cells
in culture using geldanamycinbiotin and retained on Neutra-
vidin resin after washing. HNE treatment was performed in PBS
buffer on Hsp90 bound to the Neutravidin resin. Treatment for
one hour with 500 μM HNE was followed by quenching with
10 mM NaBH4. The modified Hsp90 was then eluted from the
resin by boiling in SDS-PAGE loading buffer, purified by gel
electrophoresis, and subjected to high mass accuracy LC-MS/
MS analysis on a Thermo LTQ-Orbitrap. Peptide adduct ions
were sampled by accurate inclusion mass screening and data-
dependent MS/MS
24,28 Whereas the former method enables
targeted acquisition of MS/MS spectra for selected peptides, the
latter enables automated selection of peptide precursor ions
based on MS spectral intensities. Ideally, the combination of
these approaches enhances sampling of the most likely adducted
peptide sequences while enabling discovery of unanticipated
adducts. Predicted peptide adducts included potential cysteine
adducts and the previously reported adduction at Cys
572R.
Although none of the predicted adducts were identified, we
discovered five new sites of adduction on Hsp90β (His
171,
His
442,H i s
458,H i s
625, and His
632) as shown in Table 1.
MS/MS spectra of the peptide adducts are shown in Supporting
Information Figures 37.
Although Hsp90R was present in these experiments, we did
not identify adducts on this protein in the in vitro experiment.
UnmodiﬁedHsp90Rpeptideswerepresentinthedata-dependent
experiments, conﬁrming capture of both isoforms. However, it
appears that the relative amount of Hsp90R was lower than that
of Hsp90β, which would reﬂect the relative abundance of these
proteins in untreated cells. If formed, Hsp90R adducts may have
been below our limit of detection. All HNE adducted peptides
were identiﬁed by a +158 Da mass shift, which corresponds to
reduced Michael adducts. Measurements of the precursor ions
for each adducted peptide were within 10 ppm of predicted
values.
Analysis of Hsp90 Modification by HNE in RKO Cells. The
isolationofHsp90usinggeldanamycinbiotinallowedmonitor-
ing of the adduction of cellular Hsp90 by exogenous HNE. RKO
cells were treated with HNE at concentrations of 0, 50, 100, and
250 μM HNE for one hour. The accumulation of adducted
proteinswasvisualizedbytheimmunoblotanalysisoftreatedcell
lysates with an anti-HNE antibody (Figure 2A). The Michael
adducts of HNE in the cell lysates were reduced with 2 mM
NaBH4 before capture with geldanamycinbiotin. HNE adduc-
tion of Hsp90 captured from treated cells was visualized though
immunoblot analysis with an antibody to reduced HNE adducts,
as shown in Figure 2B. Adduction of Hsp90 by HNE was iden-
tified after only 5 min of treatment with 250 μM HNE, and the
signal increased with treatment length. After isolation of Hsp90
from HNE-treated RKO cells, the protein was gel-purified for
LC-MS/MS analysis. The protein band was excised, reduced,
alkylated, and digested with trypsin before analysis by LC-MS/MS
Figure 2. Analysis of HNE adduction in RKO cells. (A) Immunoblot
analysis of lysates from cells treated with DMSO, 50, 100, and 250 μM
HNE and detected with an antibody to reduced HNE adducts. (B)
Immunoblot analysis of Hsp90 isolated from RKO cells treated with
250 μMHNEfor0, 5,15, 30,and60minanddetectedwithanantibody
toreducedHNEadducts.LoadingcontrolfortotalHsp90detectedwith
anti-Hsp90 is shown below.
Figure 1. Geldanamycinbiotin eﬃciently captures Hsp90 from cell
lysates. (A) SDS-PAGE analysis with Coomassie staining of Hsp90
captured with geldanamycinbiotin (GM-B) or Hsp90 antibody. The
input lane contains 5 μg of cell lysate. Lanes are labeled as negative
control (), with GM-B (+), or with anti-Hsp90 (Ab). GM-B captured
protein was eluted either by boiling in SDS gel loading buﬀer (SDS) or
with2mMgeldanamycin(GM).ImmunoprecipitatedHsp90waseluted
byboilinginSDSgelloadingbuﬀer.(B)Westernblotanalysiswithanti-
Hsp90antibodyoftheﬂow-throughandelutionfromGM-Bcaptureand
immunoprecipitation of Hsp90. Lanes are labeled as ﬂow-through (FT)
oreluant(E),withelutionandcaptureconditionsnotedasin(A).Flow-
through lanes contain 2.5 μg total protein.
Table 1. Hsp90 Peptides Adducted by HNE
peptide
a in vitro
b cell treatment
c
LGIH*EDSQNR (His
450R)*
H*IYYITGETK (His
490R)*
ADH*GEPIGR (His
171β)* *
LGIH*EDSTNR (His
442β)* *
YH*TSQSGDEMTSLSEYVSR (His
458β)*
KH*LEINPDHPIVETLR (His
625β)*
HLEINPDH*PIVETLR (His
632β)*
aModiﬁed residue denoted by *.
bIn vitro treatment: 500 mM HNE for
1 h in 1 PBS.
cCell treatment: 250 mM HNE for 1 h in serum-free
medium.1279 dx.doi.org/10.1021/tx200157t |Chem. Res. Toxicol. 2011, 24, 1275–1282
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on a Thermo LTQ-Orbitrap. The Orbitrap was set with a
threshold of 100 for the data-dependent scans, which included
an accurate mass inclusion list of potential adducted peptide
masses. As shown in Table 1, four sites of adduction were
identified on Hsp90 isolated from HNE-treated RKO cells
using this data-dependent method, including two new sites
that were not identified during the in vitro treatment. The
MS/MS spectra of these two adducts are shown in Supporting
Information Figures 8 and 9. In replicate analyses, the sites
mostoftenidentifiedwereonthehomologoushistidineresidues,
His
450ofHsp90RandHis
442ofHsp90β,whichfallinthemiddle
domain of the protein and are required for binding to client
proteins.
29,30
Kinetic Analysis of Hsp90 Adduction Sites during in Vitro
Treatment of Isolated Protein. The adducts identified both in
RKO cells and in isolated Hsp90 treated with HNE were used to
create targeted methods for quantifying HNE adducts of both
Hsp90R and Hsp90β. These methods were used to measure the
observed reaction rates for each adduction site by analyzing the
extent of modification with time. The peptides for each isoform
wereanalyzedinseparateLC-MS/MSanalysesontheLTQ.The
LTQ targeted the identified peptide adduct precursor ions for
MS/MS, as well as precursors for two normalization peptides,
which were chosen for their reproducible detection and lack of
modificationbyHNEorbyoxidation.Todeterminethereaction
rate for each adduction site, the ratio of the adducted peptide
signaltotheaveragedsignalfromthenormalizationpeptideswas
calculated at each time point. This normalized signal was then
plotted as a fraction of the normalized signal for the same
adducted peptide at the chosen end point (24 h), as shown in
Figure 3A,B. These plots were then fit using a single exponential
nonlinear association to determine the kobs. The measured
reaction rates are presented in Table 2.
Kinetic Analysis of HSP90 Adduction during HNE Treat-
ment of RKO Cells in Culture. The rates of reaction for
adduction after treatment of cells with HNE are shown in
Figure 4. The measurement method was as described above,
except that 4 h was chosen as the end point. The 4 h end point
was chosen in order to maximize the potential observed adduc-
tion and to avoid complication of the analysis by biological
degradationofadductedprotein.Themeasuredreactionratesfor
three adduction sites (His
442β, His
171β, and His
450β) during cell
treatments with 250 μM HNE are given in Table 2, as well as the
calculated pKa for each adducted residue. Relative rates of adduc-
tion were measured using the targeted LC-MS/MS method
described above. Only three adduction sites on Hsp90 were
regularly observed during these experiments: His
450R, His
442β,
and His
171β. Reaction rate plots for these sites are shown in
Figure 4A,B, and the reaction rates are given in Table 2. His
450R
Figure 3. Kinetic analysis of HNE adduction sites during on-bead
treatment as analyzed by label-free relative quantitation using LC-MS/
MS. (A) Reaction rates for adduction sites on Hsp90R. Each time point
represents 36replicateanalyses. (B)Reaction ratesforadductionsites
on Hsp90β. Each time point represents 36 replicate analyses. Non-
linear single exponential regression was used to ﬁt the curves.
Table 2. kobs Values for the Reaction of HNE with Hsp90
Peptides after On-Bead and Cell Treatments
peptide
a
on-bead
kobs (h
1)
cell treatment
kobs (h
1)p Ka
b
LGIH*EDSQNR (His
450R) 0.09 ( 0.01 1.08 ( 0.17 6.78(s)
H*IYYITGETK (His
490R) 3.0  10
5 ND 4.44
ADH*GEPIGR (His
171β) 0.04 ( 0.02 0.51 ( 0.13 6.5 (s)
LGIH*EDSTNR (His
442β) 0.08 ( 0.02 0.54 ( 1.3 6.78(s)
YH*TSQSGDEMT
SLSEYVSR (His
458β)
0.04 ( 0.02 ND 4.55(b)
KH*LEINPDHPIVETLR (His
625β) 0.39 ( 0.08 ND 4.59(b)
HLEINPDH*PIVETLR (His
632β) 0.22 ( 0.10 ND 6.79(s)
aModiﬁed residue denoted by *.
bValues for pKa determined using
PROPKA online pKa calculator. (S) refers to surface residue, and (b)
refers to buried residues
Figure4. DeterminationoftherelativereactionratesofHNE-modiﬁed
Hsp90 peptides after treatment of RKO cells with 250 μM HNE.
(A) Reaction kinetics of His
450R with HNE in Hsp90R. (B) Reaction
kineticsofHis
442βandHis
171βwithHNEinHsp90β.Replicateanalyses
of 48 samples were used for each time point. Nonlinear single
exponential regression was used to ﬁt the curves.1280 dx.doi.org/10.1021/tx200157t |Chem. Res. Toxicol. 2011, 24, 1275–1282
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displayed the highest rate for both cell and in vitro treatments;
however,therateofreaction atthatresidueduringcelltreatment
was found to be an order of magnitude higher than the rate
determined from in vitro experiments. All of the rates of
adduction observed in the cell culture experiments were higher
than those observed in the in vitro treatments and ranged from
0.5 to 1 h
1.
’DISCUSSION
Eﬃcient mapping of post-translational modiﬁcations on pro-
teins often requires capture of the speciﬁc proteins of interest.
Globalaﬃnityapproachesbasedoncaptureoftheadductmoiety
do not enable selective enrichment of individual proteins.
Immunoprecipitation of epitope tagged target proteins requires
the development of expression constructs for each target protein
and the tag itself may inﬂuence both modiﬁcation of the protein
and aﬀect the level, interactions, and subcellular location of the
target. Target proteins may also be captured by immunoprecipi-
tation, but this approach is often limited by the speciﬁcity and
aﬃnity of antibodies. We demonstrate here that an aﬃnity-
tagged small-molecule inhibitor enables eﬃcient capture and
analysis of a target protein and its adducts.
ThisreportdescribestheﬁrstidentiﬁcationofHNEadductsof
Hsp90 generated within a cellular environment. Our method
allowed us not only to identify these adducts but also to study
rates of reaction of diﬀerent target sites. To accomplish this, we
have employed a high-aﬃnity small-molecule inhibitor linked to
biotin to isolate both isoforms of Hsp90 from cell lysates for
analysis by immunoblotting and LC-MS/MS. In comparison
with immunoprecipitation, small-molecule capture more eﬃ-
cientlyisolatesHsp90. The small-molecule capture methoddoes
not require the introduction of epitope-tagged Hsp90 into cells,
nor does it require the ectopic expression of elevated levels of
protein. We were thus able to evaluate Hsp90 modiﬁcations in a
native cellular context. We mapped two known phosphorylation
sites on both Hsp90 isoforms isolated from untreated cultured
RKO cells.
Our studies demonstrate the utility of a biotin-tagged, high-
aﬀnity ligand for targeted protein capture to map modiﬁcations
generated on Hsp90 by reactive species. Using capture with
geldanamycinbiotin and MS/MS analysis on a Thermo LTQ-
Orbitrap, we identiﬁed two sites of adduction by HNE on
Hsp90R and two sites of HNE adduction on Hsp90β from
RKO cells treated with 250 μM HNE. Although this concentra-
tionishigherthanendogenouslevelsofHNE(0.14μM),itwas
required to obtain a detectable extent of modiﬁcation.
31 It has
been shown that the heat shock response, in the form of Hsf1
activation, is induced in RKO cells by concentrations of HNE
greater than 50 μM.
8,32
To characterize potential sites of modiﬁcation on both iso-
forms of Hsp90, the protein was isolated using geldanamycin
biotin from untreated RKO cells and treated with HNE while it
was retained on the Neutravidin resin after isolation. This
treatment allowed the identiﬁcation of four additional adduction
sites on Hsp90β, with a data-dependent LC-MS/MS method
supplemented with an accurate inclusion mass list for detection
on a Thermo LTQ-Orbitrap. Although we regularly identiﬁed
the peptide containing unmodiﬁed Cys
572R/564β, which was
previously reported as adducted by HNE,
4 we did not detect
either cysteine adduct in our analyses. Had the adduct been
present, it should have been detected, as our analysis workﬂow
can detect HNEcysteinyl Michael adducts.
13 In considering
possible reasons for our failure to detect the cysteine adduct
reported by Carbone et al.,
4 we note ﬁrst that, according to the
crystal structure of the carboxy-terminal domain of Hsp90 from
Leishmania major (PDB: 3HJC), that residueis buried below the
protein surface. Carbone et al. detected the adduct after treat-
ment of puriﬁed protein in vitro with 0.5 mM HNE overnight,
whereas our in vitro incubations were at 0.5 mM for only 1 h. It
seems possible that some denaturation of the protein during
the longer incubation made this cysteine available for adduc-
tion in the experiments described by Carbone et al. It is also
possible that Cys
572R/564β adduction altered the bindingof Hsp90
to the geldanamycin probe, although this seems unlikely given
the ability of the probe to capture several diﬀerent modiﬁed
Hsp90 forms.
We also performed data-dependent analysis of HNE adducts
on Hsp90 from HNE-treated RKO cells. From these experi-
ments, two additional adducts, His
490R and His
450R and two
Hsp90β adducts identiﬁed during in vitro treatments were
observed. The diﬀerence in adduction sites observed between
in vitro and intact cell experiments may be due to diﬀerences in
the structures or composition of the Hsp90 complex in cells
during HNE treatment. Furthermore, the R isoform of Hsp90
may be induced during cell treatment with HNE, thus increasing
theconcentrationoftheproteinavailableforreactionwithHNE.
Two of the adduction sites we identiﬁed in Hsp90 from treated
cells, His
450R/His
442β, are homologous in Hsp90R and Hsp90β.
The adduction site His
490R is found only in Hsp90R and is
replaced by a serine in the β isoform. Conversely, His
171β is
adducted in the N-terminal region of Hsp90β, and is notpresent
in the R isoform.
Using in vitro HNE treatment of isolated Hsp90 and targeted
LC-MS/MS analysis, we were able to measure the kinetics of
modiﬁcation of speciﬁc residues on Hsp90 R and β. The
precursor ions corresponding to the modiﬁed peptides were
targeted for MS/MS. For quantiﬁcation, signals for the expected
fragment ions were extracted and then normalized to signals
obtained from two unmodiﬁed peptides from each Hsp90 iso-
form.Thisnormalizationstepcorrectedfordiﬀerencesincapture
eﬃciency or recovery of Hsp90 protein and enabled data from
multiple independent capture preparations to be compared. All
seven adduction sites gave suﬃcient data for kinetic character-
ization. We did not track the potential doubly adducted peptide
containing both His
632β and His
625β because we did not observe
thatbis-adduct inour mappingexperiments.Thisstudy was only
the second report, to our knowledge, to compare kinetics of
protein adductionat diﬀerent sites inaprotein inintact cells. We
previously employed a similar approach to compare kinetics of
cysteine residue modiﬁcations in the sensor protein Keap1.
33
To understand the observed kinetic reaction rates of the
various adduction sites on Hsp90, we calculated the pKa of each
histidine residue using the PROPKA online algorithm (http://
propka.ki.ku.dk/). We had previously found that the pKa of His
residues in human albumin correlated with measured reaction
rate constants.
6 For the adducted residues of Hsp90β, it was ﬁrst
necessary to create a homology model containing the residues of
interest. Using the Swiss-model algorithm (www.swissmodel.
expasy.org), we threaded the amino acid sequence (Uniprot:
PO8238) onto the crystal structure of the c-terminus of Hsp90
from Leishmania major (PDB: 3HJC), which displayed the
highest sequence identity to the human protein. This produced
a homology model with a root-mean-square deviation from the1281 dx.doi.org/10.1021/tx200157t |Chem. Res. Toxicol. 2011, 24, 1275–1282
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original crystal structure of 2.38 Å. Using this homology model,
the pKa values of the adducted histidines were predicted
(Table 2). PROPKA also predicts whether a residue is surface-
exposed or buried. In particular, all the cysteines in the carboxyl-
terminal region of Hsp90β except Cys
632 are predicted to be
buried. The HNE target residue, Cys
572R/564β, previously ob-
served by Carbone et al., was calculated to have a pKa of 9.0 and
to be buried within the structure.
From our preliminary kinetic analysis of HNE adduction
duringinvitrotreatmentofisolatedHsp90Randβ,tworesidues,
His
625β and His
632β, displayed the highest overall reactivity, with
kobs rates of 0.39 and 0.22 h
1, respectively. His
625β reacts
slightly faster than His
632 despite the potential occlusion of its
imidazole ring by a ridge on the Hsp90 protein, as shown in
Figure 5A. This correlates with the predicted pKa of His
625β
(4.59) being lower than the predicted pKa of His
632β (6.79),
which resides directly on the surface of the protein (Figure 5B).
The homologous histidines, His
442β and His
450R, are char-
acterized by similar reaction rates during the on-bead treatment.
These residues are C-terminal to a region shown to be required
for Hsp90 chaperone activity toward both the estrogen receptor
and the progesterone receptor, although the region including
His
442βwasnotdirectly analyzedinthestudy.
29Surprisingly,the
observed reaction rates of His
450R and His
442β during cellular
treatment with HNE diﬀer by a factor of 2 and both rates are
almost an order of magnitude higher than the values measured
for isolated Hsp90 in vitro. The same observation holds true for
adduction ofHis
171β;theinvitroadduction exhibited arelatively
lowobservedrateof0.04h
1,whereastherateobtainedfromcell
treatmentwas0.51h
1.Thisdiﬀerencemaybeduetothealtered
structureofHsp90uponbindingtogeldanamycinduringtheon-
bead reactions or to changes in the N-terminal domain with
cochaperone or client protein binding in the cell.
’CONCLUSION
Wedevelopedaninhibitor-basedcapturemethodforLC-MS/
MS analysis of Hsp90 that aﬀords good yield and suﬃcient
coverage of the protein. Our analyses identiﬁed several new
adduction sites on Hsp90 formed by in vitro HNE treatment of
the captured proteins. We were also able to identify a smaller
number of adduction sites on Hsp90 following HNE treatment
of RKO cells followed by geldanamycinbiotin capture and LC-
MS/MS analysis. The detection of a fewer adducts on Hsp90 in
intact cells may reﬂect interactions with client proteins, which
mayobscurebindingsitesthatareavailableintheisolatedprotein
in vitro. The use of the geldanamycinbiotin probe could be
adapted for studies of other reactive species thought to modify
Hsp90. Moreover, the approach of using high-aﬃnity, small-
molecule probes linked to biotin oﬀers a useful strategy for
targeted analysis of protein modiﬁcations by endogenous and
exogenous electrophiles.
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